Table 1.
Clinical, biochemical and angiographic characteristics of all study groups
|
UA group (n = 76) |
SCAD group (n = 165) |
Control group (n = 85) |
|
|---|---|---|---|
| Males/females | 55/21 | 112/53 | 60/25 |
| Age (year) | 66 ± 12 | 68 ± 12 | 64 ± 12 |
| Smoking, n | 52 (68.4%) | 16 (9.8%) | 30 (35.3%)*# |
| Hypertension, n | 59 (77.6%) | 131 (79.4%) | 48 (56.5%)* |
| Diabetes, n | 21 (27.6%) | 42 (25.5%) | 15 (17.6%) |
| Statins, n | 45 (59%) | 159 (96.4%) | 29 (34.1%)*# |
| BMI (kg/m2) | 30.42 ± 5.92 | 29.58 ± 3.71 | 29.4 ± 3.42 |
| SBP (mmHg) | 138 ± 24 | 132 ± 18 | 128 ± 15# |
| ABI | 1.12 ± 0.31 | 0.98 ± 0.26 | 1.17 ± 0.39 |
| DBP (mmHg) | 81 ± 15 | 81 ± 11 | 77 ± 14 |
| LVEF (%) | 59 ± 10 | 61 ± 8 | 62 ± 7 |
| TChol (mg/dl) | 205 ± 36 | 165 ± 36 | 212 ± 48* |
| HDL-C (mg/dl) | 39 ± 10 | 44 ± 17 | 47 ± 13# |
| LDL-C (mg/dl) | 134 ± 61 | 95 ± 31 | 140 ± 40* |
| TG (mg/dl) | 158 ± 92 | 128 ± 65 | 127 ± 73 |
| FPG (mg/dl) | 140 ± 57 | 131 ± 40 | 125 ± 32 |
| HbA1c (%)a | 7.6 ± 1 | 7.2 ± 1.1 | 7.1 ± 0.8 |
| Insulin (mU/l) | 12.2 ± 5.90 | 11.35 ± 5.02 | 9.01 ± 4.73 |
| HOMA-IR | 4.22 ± 1.91 | 3.67 ± 1.25 | 2.78 ± 1.18# |
| hsCRP (mg/l) | 5.98 ± 2.562 | 3.59 ± 1.16 | 2.12 ± 0.88# |
| Nesfatin-1 (pg/ml) | 331.75 ± 101.22 | 416.51 ± 119.83 | 515.12 ± 111.85#* |
| DPP4 (ng/dl) | 81.92 ± 20.21 | 65.35 ± 14.67 | 42.81 ± 10.66#* |
n number of patients, BMI body-mass index, SBP systolic blood pressure, DBP diastolic blood pressure, ABI ankle-brachial index, LVEF left ventricular ejection fraction, TChol total cholesterol, TG triglycerides, FPG fasting plasma glucose, HOMA-IR homeostasis model assessment-insulin resistance, hsCRP high-sensitivity CRP, DPP4 Dipeptidyl peptidase 4
#UA vs. control group p < 0.05
*SCAD vs. control group p < 0.05
aHbA1c was measured only in the diabetic subgroup